Close Menu

Eisai

H3, a subsidiary of Japanese drugmaker Eisai, is developing personalized cancer treatments targeting genomic alterations, including aberrant RNA splicing.

Cancer Genetics will provide the services to support H3's development of H3B-8800, a Phase I small molecule-based blood cancer drug candidate.

The companies said they aim to discover next-generation tests that will enable early diagnosis of dementia, as well as treatment selection and monitoring.

Under the terms of the deal, Oncodesign will conduct in vivo pharmacology studies, while Eisai will do gene expression analysis.

Given its interest in developing treatments for Alzheimer's disease (AD), Japanese drugmaker Eisai is exploring the potential of plasma-based microRNAs to serve as biomarkers for the disease.

Seegene and Eidia, the in vitro diagnostics subsidiary of Japanese pharmaceutical firm Eisai, have entered into a collaborative agreement to bring new multiplex molecular diagnostic tests to Japan.

NEW YORK (GenomeWeb News) – Seegene announced today that it has signed an agreement with Eidia to market the firm's molecular diagnostic products in Japan.

Epizyme this week announced a collaboration with Eisai and Roche to develop an in vitro, PCR-based companion diagnostic test to help treat genetically defined lymphomas.

NEW YORK (GenomeWeb News) — Epizyme today announced a collaboration with Eisai and Roche to develop an in vitro, PCR-based companion diagnostic test to help treat genetically defined lymphomas.

NEW YORK (GenomeWeb News) – Japanese drug firm Eisai and its diagnostics subsidiary Eidia said today that they are dissolving their diagnostics R&D subsidiary, Palma Bee'Z Research Institute, as part of the Eisai Group's transformation of its in vitro diagnostics development operations.

Pages

Two researchers are calling for education for scientists on defending facts.

Researchers were among those who marched in London this weekend to call for another vote on Brexit.

Duke has agreed to pay $112.5 million to settle a lawsuit regarding its handling of data falsified by biologist Erin Potts-Kant. 

In PLOS this week: genetic factors influencing inorganic arsenic metabolism and toxicity, a germline variant in the cell adhesion molecule-coding gene DSCAM, and more.